NAFDAC approves Pfizer-BioNTech Covid vaccine for emergency use

By our reporter| The National Agency for Food and Drug Administration and Control on Friday announced that it has approved Pfizer-BionTech COVID-19 vaccine for emergency use in Nigeria.

NAFDAC DG, Prof Mojisola Adeyeye who made the disclosure at the agency headquarters in Lagos, said the approval given was not a full one but it would be in effect within the period of getting people vaccinated and gathering data about the adverse effects following immunisation.

According to her, The NAFDAC NAFDAC relied on a more mature regulatory body for its approval, adding that that the agency was at liberty to review its stance since the World Health Organisation had given emergency use listing.

See also  SSS to arraign El-Rufai on Wednesday for cybercrime, national security breach

“The purpose of the press briefing is to announce that NAFDAC has just approved Pfizer-BionTech vaccines for possible use in Nigeria, she said.

“They were reviewed carefully by the NAFDAC staff COVID-19 vaccine committee to make sure that the science behind the development is well understood and in accord with our world regulatory activities.

“We used different mechanisms to approve the vaccine. We used reliance, meaning that a more mature regulatory agency across the globe, we can use that as a basis for our review.

“We will get the assessment report, know the peculiarity there, then our COVID-19 committee will get to do their job.”

Nigeria commenced its vaccination programme against the novel coronavirus last month with 3.924m doses of AstraZeneca vaccine doses.

See also  DMO: Nigeria’s public debt stock rose by N900bn to N153trn in Q3 2025

According to the National Primary Health Care Development Agency, over one million doses of the vaccine have so far been administered across the country in the first phase of the vaccination programme.

NAFDAC had earlier approved AstraZeneca vaccine for use in Nigeria.

Leave a Reply